Other Academic

Renato Umeton

Visting Scientist

Biostatistics

renato_umeton@dfci.harvard.edu

Links

Overview

Affiliate, Dana-Farber Cancer Institute
Affiliate, Massachusetts Institute of Technology
Affiliate, Harvard T.H. Chan School of Public Health
Affiliate, Weill Cornell Medical

Bibliography

Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study.

Ferraldeschi M, Romano S, Giglio S, Romano C, Morena E, Mechelli R, Annibali V, Ubaldi M, Buscarinu MC, Umeton R, Sani G, Vecchione A, Salvetti M, Ristori G.

Front Neurol. 2021. 12:657973. PMID: 34025560

Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.

Penney KL, Tyekucheva S, Rosenthal J, El Fandy H, Carelli R, Borgstein S, Zadra G, Fanelli GN, Stefanizzi L, Giunchi F, Pomerantz M, Peisch S, Coulson H, Lis R, Kibel AS, Fiorentino M, Umeton R, Loda M.

Mol Cancer Res. 2021 03. 19(3):475-484. PMID: 33168599

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.

Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM.

Ann Oncol. 2020 06. 31(6):807-814. PMID: 32171752

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.

Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML.

Clin Cancer Res. 2020 08 01. 26(15):4135-4142. PMID: 32332016

Automated machine learning: Review of the state-of-the-art and opportunities for healthcare.

Waring J, Lindvall C, Umeton R.

Artif Intell Med. 2020 04. 104:101822. PMID: 32499001

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.

Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, Cherniack AD, Price KS, Fairclough SR, Nishino M, Sholl LM, Oxnard GR, Jänne PA, Awad MM.

Clin Cancer Res. 2020 06 01. 26(11):2615-2625. PMID: 32034073

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.

Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Van Allen EM, Tolaney SM.

Clin Cancer Res. 2020 06 01. 26(11):2565-2572. PMID: 32019858

Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis.

Mechelli R, Umeton R, Manfrè G, Romano S, Buscarinu MC, Rinaldi V, Bellucci G, Bigi R, Ferraldeschi M, Salvetti M, Ristori G.

Genes (Basel). 2020 01 14. 11(1). PMID: 31947683

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM.

JCO Precis Oncol. 2019. 3. PMID: 31832578

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.

Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM.

J Immunother Cancer. 2019 03 28. 7(1):87. PMID: 30922388

VIEW MORE PUBLICATIONS